已收盘 12-19 16:00:00 美东时间
-0.330
-2.16%
Seres Therapeutics reports new data on SER-155 demonstrating its potential to promote T-cell recovery, reduce bloodstream infections, and improve outcomes after allo-HSCT.
05-27 11:00
Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock increased by 16.8% to $0....
2024-09-27 04:31
Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or the "Company"), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the
2024-09-27 04:03
Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $10 price target.
2024-09-14 02:38